1. Towards better patient care: drugs to avoid in 2014 ―Prescrire International English
– Medicamentos peligrosos (By Prescrire): analysis by Plataforma NoGracias.
– Boletin Med-Informatica, Federación Médica Colombiana.
PRESCRIRE Internacional Incluye Sitagliptina, Saxagliptina y Linagliptina en Lista Negativa de Medicamentos Inservibles (2014).
2. BMJ Open Data Campaign: Incretin Mimetics
“Incretin therapies—glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors—looked as if they might change the face of type 2 diabetes. Their dual action of switching on insulin and suppressing glucagon to help control blood glucose has been hailed as the biggest breakthrough since the discovery of insulin. And they may soon also be licensed for treating obesity.
But a BMJ investigation published in June 2013 and accompanying Channel 4Dispatches programme found growing safety concerns linked to the drugs’ mechanism of action and asked why doctors and patients have not been told.
Concerns held by some specialists about the potential side effects emerged after the FDA and the European Medicines Agency announced in March 2013 that they would launch a review into whether the drugs may cause or contribute to the development of pancreatic cancer.
The saliva of the desert dwelling Gila monster (pictured) was the source for the first GLP-1 analogue on the market, exenatide. A heavy slow moving lizard, it eats once or twice a year, and uses the secretion of its salivary hormone exendin-4—which displays similar properties to GLP-1—to induce proliferation of its pancreas and gut to assimilate a meal.
This page links to the investigation and accompanying commentaries, a BMJ video about the science behind the story, and a timeline showing what happened when. You can also see the correspondence trail between BMJ investigations editor Deborah Cohen and the drug companies with an interest in developing insulin mimetic drugs.”
- Investigation: Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
- Questions posed to manufacturers and regulators
- Feature: Incretins and risk of neoplasia
- Editorial: Incretin therapy: should adverse consequences have been anticipated?
- Editorial: Helping patients make sense of the risks of taking GLP-1 agonists
- Editor’s choice: Secrecy does not serve us well
- Video: The science behind the story
- Timeline: What happened when in the GLP-1 story
- News: Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation”
- News: Pressure mounts for companies to hand over data on antidiabetes drugs linked to pancreatic harm
Like I said on the title on the rapid response: Let’s start this once again, I’ll not stop until no doubts will remain about the safety and effectiveness of incretin mimetics as pharmacological treatments in diabetes type 2. Why so many clinical trials evaluating the effects of incretins are unpublished?
“Somewhere, something incredible is waiting to be known.” – Carl Sagan
“Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage” – Re: let’s start this discussion again. http://www.bmj.com/content/347/bmj.f4386/rr/763130
Ramirez, Jorge H (2014): Analysis of published and unpublished liraglutide studies in humans. figshare. http://dx.doi.org/10.6084/m9.figshare.1134664
Ramirez, Jorge H (2014): Incretin mimetics: analysis of published & unpublished studies. figshare. http://dx.doi.org/10.6084/m9.figshare.1104132